ALGS
Aligos Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$50.06M
P/E Ratio
—
EPS
$-2.45
Beta
2.62
52W High
$13.69
52W Low
$3.76
50-Day MA
$7.27
200-Day MA
$8.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $2.19M |
| Gross Profit (TTM) | $-67.27M |
| EBITDA | $-87.06M |
| Operating Margin | -12908.00% |
| Return on Equity | -196.90% |
| Return on Assets | -69.30% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $8.67 |
| Price-to-Book | 0.92 |
| Price-to-Sales (TTM) | 22.90 |
| EV/Revenue | 0.477 |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -73.10% |
| Shares Outstanding | $5.39M |
| Float | $3.64M |
| % Insiders | 10.30% |
| % Institutions | 55.75% |
Analyst Ratings
Consensus ($65.80 target)
1
Strong Buy4
BuyData last updated: 4/7/2026